普通人群肝脏受控衰减参数的多元回归分析*

doi:10.3969/j.issn.1672-5069.2014.03.018

Abstract

Abstract: Objective To explore the related factors of controlled attenuation parameter （CAP） of liver obtained by FibroScan examination in healthy individuals. Methods The CAP was obtained by FibroScan in208healthy persons, and the main biochemical indexes, gender, age, body mass index （BMI）, waist-hip ratio （WHR）, waist-height ratio were collected at the same time, and the relationship between CAP value, these common indicators was analyzed. Results Multiple linear regression analysis showed that CAP value was significantly correlated with BMI, WHR, age （for BMI, β=0.280, P=0.0002;for WHR, β=0.206, P=0.0059;for age, β=0.192, P=0.0022）;And the regression equation established after multiple linear regression analysis, partial least squares regression were CAP=-137.70+9.40*TG+5.40*BMI+176.34*WHR+1.60*age, the adjusted CAP=-92.11+10.67*TG-10.25*HDL+4.45*BMI+196.25*WHR+1.03*age. Conclusions The range of CAP value is affected by BMI, WHR, and age in the general population, the adjusted regression equation is more better to predict the CAP value of the liver

Key words: Liver steatosis, FibroScan, Controlled attenuation parameter, Regression equation

Lu Jiafa,Pan Qin,Chen Guangyu. Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy individuals[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 291-295.

References

[1] Dowman JK,Tomlinson JW,Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2011,33（5）:525-540.
[2] Ratziu V,Charlotte F,Heurtier A,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology,2005,128（7）:1898-1906.
[3] Regev A,Berho M,Jeffers LJ,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol, 2002,97:2614-2618.
[4] Saadeh S,Younossi ZM,Remer EM,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology,2002,123（3）: 745-750.
[5] Schwenzer NF,Springer F,Schraml C,et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol,2009,51（3）:433-445.
[6] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter （CAP）:a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36（11）:1825-1835.
[7] De Ledinghen V,Vergniol J,Foucher J,et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter （CAP） and transient elastography. Liver Int,2012,32（6）:911-918.
[8] Myers RP,Pollett A,Kirsch R,et al. Controlled attenuation parameter （CAP）:a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int,2012,32（6）:902-910.
[9] Sasso M,Tengher-Barna I,Ziol M,et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan:validation in chronic hepatitis. C. J Viral Hepat,2012,19（4）:244-253.
[10] Kumar M,Rastogi A,Singh T,et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis:Does etiology affect performance J Gastroenterol Hepatol,2013,28（7）:1194-1201.
[11] Andersen ES,Christensen PB,Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med,2009,20（4）：339-342.
[12] Wong GLH.Transient elastography:Kill two birds with one stone World J Hepatol,2013,5（5）:264-274.
[13] Degos F,Perez P,Roche P,et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis:A multicenter prospective study （the FIBROSTIC study）. J Hepatol,2010,53（6）:1013-1021.
[14] 沈峰,潘勤,范建高,等. FibroScan:实施受控衰减参数评价脂肪肝的影响因素及重复性分析. 实用肝脏病杂志,2013,16（1）:59-62.
[15] Chon YE,Jung KS,Kim SU,et al. Controlled attenuation parameter （CAP） for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int, 2013,34（1）:102-109.
[16] Masaki K,Takaki S,Hyogo H,et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res,2013,43（11）:1182-1189.
[17] Xu C,Yu C,Ma H,et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study. Am J Gastroenterol,2013,108（8）:1299-1304.
[18] Nascimbeni F,Pais R,Bellentani S,et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013,59（4）:859-871.
[19] 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议.实用肝脏病杂志,2013,16（3）:207-209.

Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy individuals

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[4]	Wang Qian,Guo Ping. Application of fibroscan and anthropometric parameters in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 754-755.
[5]	Sun Changgui， Zeng Jing，Sun Wanlu，et al.. Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 165-170.
[6]	Qian Peiguo, Lian Xiaoxiao, Guo Xiaoxia.. Application of noninvasive diagnostic model in diagnosis of liver fibrosis in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 578-582.
[7]	Zeng Jing, Chen Guangyu, Pan Qin, e t al. Detection of controlled attenuation parameter of spleen in diagnosis of fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 445-450.
[8]	Yang Shuo, Lyu Dong, Wang Tianyi, Zhang Longyou, Xu Youqing. Diagnostic efficacy of FibroTouchR by measuring fat attenuation index in detecting liver steatosis in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 50-54.
[9]	Wang Wenrui，Yang Lanlan，Jia Shengnan，et al.. Influencing factors of controlled attenuation parameter by FibroTouch in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 367-370.
[10]	. FibroScan is a new apparatus allowing noninvasive quantification of liver fibrosis by measuring the stiffness of the liver in patients with alcohol abuse [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(4): 303-304.